source
- Ionis secures FDA approval for Zanvastro, first disease-modifying therapy for rare Alexander diseaseIonis Pharmaceuticals announced that the U.S. Food and Drug Administration has approved Zanvastro, marking the first disease-modifying treatment for Alexander disease, a rare and often fatal neurol…
- Revolution Medicines' Rasonque shows 42% response and 16-month survival in NSCLC subgroupData from a subgroup of an earlier trial, described by Truist Securities as the most relevant to Revolution Medicines' ongoing Phase 3 study, reported a 42% overall response rate and a median overa…